Schizophrenia might be treated by folic acid, vitamin B12 and vitamin D

Created May 2014

Vitamin Supplementation in the Treatment of Schizophrenia.

CNS Drugs. 2014 May 21. [Epub ahead of print]

Brown HE 1, Roffman JL.

1 Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA, [email protected].

This article reviews the current literature addressing the treatment of schizophrenia with vitamin supplementation. It describes the important roles that vitamins play in normal metabolism, and reviews the evidence pertaining to vitamin deficiency and supplementation in patients with schizophrenia. There is mounting evidence suggesting that vitamin supplementation, in particular with, may be important in treatment within certain subgroups of patients. There is a need for larger randomized controlled trials, and further studies examining the incidence of schizophrenia in countries with poor prenatal care and malnutrition, as well as in countries that have adopted mandatory folic acid fortification of grain products, are recommended.

PMID: 24846474

Publisher charges $50 for the PDF

References

  1. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137(1–3):147–50. doi:10.1016/j.schres.2012.01.015. CrossRef

  2. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79–104. doi:10.1038/sj.mp.4001556. CrossRef

  3. Kemperman RF, Veurink M, van der Wal T, Knegtering H, Bruggeman R, Fokkema MR, et al. Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins Leukot Essent Fatty Acids. 2006;74(2):75–85. doi:10.1016/j.plefa.2005.11.004. CrossRef

  4. Muntjewerff JW, van der Put N, Eskes T, Ellenbroek B, Steegers E, Blom H, et al. Homocysteine metabolism and B-vitamins in schizophrenic patients: low plasma folate as a possible independent risk factor for schizophrenia. Psychiatry Res. 2003;121(1):1–9. CrossRef

  5. Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, et al. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res. 2010;175(1–2):47–53. doi:10.1016/j.psychres.2009.01.013. CrossRef

  6. Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry. 2004;161(9):1705–8. doi:10.1176/appi.ajp.161.9.1705. CrossRef

  7. Menkes DB, Lancaster K, Grant M, Marsh RW, Dean P, du Toit SA. Vitamin D status of psychiatric inpatients in New Zealand’s Waikato region. BMC Psychiatry. 2012;12:68. doi:10.1186/1471-244X-12-68. CrossRef

  8. Berg AO, Melle I, Torjesen PA, Lien L, Hauff E, Andreassen OA. A cross-sectional study of vitamin D deficiency among immigrants and Norwegians with psychosis compared to the general population. J Clin Psychiatry. 2010;71(12):1598–604. doi:10.4088/JCP.09m05299yel. CrossRef

  9. Gracious BL, Finucane TL, Friedman-Campbell M, Messing S, Parkhurst MN. Vitamin D deficiency and psychotic features in mentally ill adolescents: a cross-sectional study. BMC Psychiatry. 2012;12:38. doi:10.1186/1471-244X-12-38. CrossRef

  10. Crews M, Lally J, Gardner-Sood P, Howes O, Bonaccorso S, Smith S, et al. Vitamin D deficiency in first episode psychosis: a case-control study. Schizophr Res. 2013;150(2–3):533–7. doi:10.1016/j.schres.2013.08.036. CrossRef

  11. Belvederi Murri M, Respino M, Masotti M, Innamorati M, Mondelli V, Pariante C, et al. Vitamin D and psychosis: mini meta-analysis. Schizophr Res. 2013;150(1):235–9. doi:10.1016/j.schres.2013.07.017. CrossRef

  12. Suboticanec K, Folnegovic-Smalc V, Turcin R, Mestrovic B, Buzina R. Plasma levels and urinary vitamin C excretion in schizophrenic patients. Human Nutr Clin Nutr. 1986;40(6):421–8.

  13. D’Souza B, D’Souza V. Oxidative injury and antioxidant vitamins E and C in Schizophrenia. Indian J Clin Biochem IJCB. 2003;18(1):87–90. doi:10.1007/BF02867671. CrossRef

  14. Lieberman MMA, Peet A. Marks’ basic medical biochemistry: a clinical approach. 4th ed. Philadelphia: PA Lippincott Williams & Wilkins; 2013.

  15. http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/LabelingNutrition/ucm064928.htm. Accessed November 15 2013.

  16. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res. 2013;47(2):197–207. doi:10.1016/j.jpsychires.2012.10.005. CrossRef

  17. Hoffer A. Nutrition and schizophrenia. Can Fam Phys Med Fam Can. 1975;21(4):78–82.

  18. Hoffer A, Prousky J. Successful treatment of schizophrenia requires optimal daily doses of vitamin B3. Altern Med Rev J Clin Ther. 2008;13(4):287–91.

  19. Petrie WM, Ban TA. Vitamins in psychiatry. Do they have a role? Drugs. 1985;30(1):58–65. CrossRef

  20. Haidemenos A, Kontis D, Gazi A, Kallai E, Allin M, Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog Neuro-psychopharmacol Biol Psychiatry. 2007;31(6):1289–96. doi:10.1016/j.pnpbp.2007.05.011. CrossRef

  21. Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, Henderson DC, et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry. 2008;63(1):42–8. doi:10.1016/j.biopsych.2006.12.017. CrossRef

  22. Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, Henderson DC, Wong DH, et al. Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia. Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2008;147B(6):990–5. doi:10.1002/ajmg.b.30684. CrossRef

  23. Roffman JL, Gollub RL, Calhoun VD, Wassink TH, Weiss AP, Ho BC, et al. MTHFR 677C → T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val → Met. Proc Natl Acad Sci USA. 2008;105(45):17573–8. doi:10.1073/pnas.0803727105. CrossRef

  24. Roffman JL, Nitenson AZ, Agam Y, Isom M, Friedman JS, Dyckman KA, et al. A hypomethylating variant of MTHFR, 677C > T, blunts the neural response to errors in patients with schizophrenia and healthy individuals. PloS one. 2011;6(9):e25253. doi:10.1371/journal.pone.0025253. CrossRef

  25. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature Genet. 2008;40(7):827–34. doi:10.1038/ng.171. CrossRef

  26. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336(8712):392–5. CrossRef

  27. Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biological Psychiatry. 2006;60(3):265–9. doi:10.1016/j.biopsych.2005.10.009. CrossRef

  28. Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res. 2011;127(1–3):41–5. doi:10.1016/j.schres.2010.12.006. CrossRef

  29. Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry. 2013;70(5):481–9. doi:10.1001/jamapsychiatry.2013.900. CrossRef

  30. Fatemi SH. Co-occurrence of neurodevelopmental genes in etiopathogenesis of autism and schizophrenia. Schizophr Res. 2010;118(1–3):303–4. doi:10.1016/j.schres.2010.01.018. CrossRef

  31. Susser E, Neugebauer R, Hoek HW, Brown AS, Lin S, Labovitz D, et al. Schizophrenia after prenatal famine. Further evidence. Arch General Psychiatry. 1996;53(1):25–31. CrossRef

  32. St Clair D, Xu M, Wang P, Yu Y, Fang Y, Zhang F, et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959–1961. JAMA J Am Med Assoc. 2005;294(5):557–62. doi:10.1001/jama.294.5.557. CrossRef

  33. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338(8760):131–7.

  34. Brown AS, Susser ES. Prenatal nutritional deficiency and risk of adult schizophrenia. Schizophr Bull. 2008;34(6):1054–63. doi:10.1093/schbul/sbn096. CrossRef

  35. Brown AS, Bottiglieri T, Schaefer CA, Quesenberry CP Jr, Liu L, Bresnahan M, et al. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch General Psychiatry. 2007;64(1):31–9. doi:10.1001/archpsyc.64.1.31. CrossRef

  36. Dealberto MJ. Clinical symptoms of psychotic episodes and 25-hydroxy vitamin D serum levels in black first-generation immigrants. Acta Psychiatrica Scand. 2013;128(6):475–87. doi:10.1111/acps.12086. CrossRef

  37. Graham KA, Keefe RS, Lieberman JA, Calikoglu AS, Lansing KM, Perkins DO. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early intervention in psychiatry. 2014. doi:10.1111/eip.12122.

  38. McGrath JJ, Eyles DW, Pedersen CB, Anderson C, Ko P, Burne TH, et al. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch General Psychiatry. 2010;67(9):889–94. doi:10.1001/archgenpsychiatry.2010.110. CrossRef

  39. Sullivan S, Wills A, Lawlor D, McGrath J, Zammit S. Prenatal vitamin D status and risk of psychotic experiences at age 18 years-a longitudinal birth cohort. Schizophr Res. 2013;148(1–3):87–92. doi:10.1016/j.schres.2013.05.015. CrossRef

  40. McGrath J, Saari K, Hakko H, Jokelainen J, Jones P, Jarvelin MR, et al. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr Res. 2004;67(2–3):237–45. doi:10.1016/j.schres.2003.08.005. CrossRef

  41. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res. 2003;62(3):195–204. CrossRef

  42. Bentsen H, Osnes K, Refsum H, Solberg DK, Bohmer T. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E + C in schizophrenia. Transl Psychiatry. 2013;3:e335. doi:10.1038/tp.2013.110. CrossRef

  43. Beauclair L, Vinogradov S, Riney SJ, Csernansky JG, Hollister LE. An adjunctive role for ascorbic acid in the treatment of schizophrenia? J Clin Psychopharmacol. 1987;7(4):282–3. CrossRef

  44. Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology. 2005;182(4):494–8. doi:10.1007/s00213-005-0117-1. CrossRef

  45. Bao Y, Ibram G, Blaner WS, Quesenberry CP, Shen L, McKeague IW, et al. Low maternal retinol as a risk factor for schizophrenia in adult offspring. Schizophr Res. 2012;137(1–3):159–65. doi:10.1016/j.schres.2012.02.004. CrossRef

  46. Mason JB. Unraveling the complex relationship between folate and cancer risk. BioFactors. 2011;37(4):253–60. doi:10.1002/biof.174. CrossRef

  47. Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet. 2013;381(9871):1029–36. doi:10.1016/S0140-6736(12)62001-7. CrossRef

See also Vitamin D Life

Tags: B12 Cognitive